London, United Kingdom
Antibody Design is a young and innovative biotech startup, founded in 2022, and headquartered in the United Kingdom. The company operates at the cutting edge of deep tech and biotechnology, aiming to revolutionize the field with their next-generation, AI-driven rapid diagnostics capabilities. Their aspiration is to merge technology and biology to create smarter, more connected healthcare solutions.
Despite its infancy, Antibody Design has already caught the attention of early-stage investors, securing an investment of £150.00K from SFC Capital in an Early VC round on 01 June 2023. This funding signifies investor confidence in their potential to disrupt the biotech industry with groundbreaking innovation.
With its strategic focus and recent infusion of capital, Antibody Design is positioned to leverage advancements in AI and biotechnology, offering compelling growth and partnership opportunities for forward-thinking investors.
